Today: 21 May 2026
Carvana stock sinks nearly 20% after Gotham short-seller report; Wall Street eyes earnings next
28 January 2026
2 mins read

Carvana stock sinks nearly 20% after Gotham short-seller report; Wall Street eyes earnings next

New York, January 28, 2026, 14:23 (EST) — Regular session

  • Carvana shares tumbled following a Gotham City Research report that raised concerns over accounting practices and related-party disclosures.
  • The short seller claimed earnings for 2023-2024 were overstated by over $1 billion.
  • Investors are awaiting the company’s response before the upcoming earnings report.

Shares of Carvana Co plunged roughly 19.5% to $384.57 Wednesday afternoon after short seller Gotham City Research released a report accusing the company of accounting irregularities and undisclosed related-party deals. The stock had closed Tuesday at $477.72 and fluctuated between $375.13 and $482.31 during the session. Carvana did not immediately respond to requests for comment.

This hit matters since Carvana has been one of the market’s most polarizing turnaround stories, with investors divided over the durability of its profits and the reliance on credit markets. A short report targeting earnings quality can quickly push fast money out, leaving questions to follow.

The timing couldn’t be worse. Carvana faces a crucial reporting period and refinancing buzz, and the stock isn’t tolerant of negative news.

Gotham’s report claims Carvana overstated its 2023-2024 earnings by over $1 billion and leaned more heavily on related parties than previously revealed. The firm pointed to DriveTime’s leverage as a key factor propping up Carvana’s adjusted EBITDA — a profit metric excluding interest, taxes, and other costs. DriveTime reportedly burned through more than $1 billion in cash over 2023 and 2024, according to financials Gotham says it obtained via the Freedom of Information Act. The report also forecasts a delayed 2025 10-K filing and potential restatements of past annual reports, highlighting auditor Grant Thornton as a possible weak link.

Gotham flagged “problems with accounting, disclosure, and business practices” that could trigger regulatory issues. Yet some major brokers are still optimistic: JPMorgan bumped its price target to $510 from $490 on Wednesday, maintaining an Overweight rating. Wells Fargo’s David Lantz also raised his target, from $500 to $525, keeping his Overweight call, according to notes cited by Stocktwits. Stocktwits

Carvana will release its fourth-quarter and full-year 2025 earnings after the market closes on February 18, the company announced. A conference call is set for later that evening.

Shares have climbed from a 2022 low near $4 to about $473 earlier this month, a surge that made the stock vulnerable to a sharp pullback if doubts surfaced. Carvana has weathered short-seller attacks before and fought back, calling itself “one of the most heavily researched public companies” while labeling the claims as “intentionally misleading and inaccurate,” the Financial Times reported. Financial Times

Carvana goes head-to-head with used-car sellers like CarMax and a sprawling network of dealers and online sites. Yet, its approach relies heavily on financing and securitisation to push inventory out the door and bankroll customer loans. This setup means any controversy around how it records loan gains and related-party transactions remains a hot topic for shareholders.

The downside is clear. Should the short seller’s allegations trigger regulatory probes, restatements, or stricter lender and counterparty reactions, the stock could slide sharply. On the flip side, a strong refutation or clean filings without any surprises might stabilize it just as swiftly.

Traders are focusing on any corporate response and what management reveals on February 18 regarding related-party connections, loan-sale accounting, and the details behind its profit figures.

Stock Market Today

  • SpaceX IPO Filing Reveals Financials, Musk Could Become First Trillionaire
    May 20, 2026, 7:08 PM EDT. SpaceX filed for an initial public offering (IPO), disclosing its finances and board members for the first time. The company reported $18.7 billion in revenue for 2025, up 33% year-on-year, but posted a net loss of $4.9 billion, reversing a $791 million profit in 2024. First-quarter 2026 losses reached $4.3 billion on $4.7 billion revenue. The IPO, trading as SPCX, may become the largest ever, potentially boosting Elon Musk's wealth to trillionaire status. SpaceX aims to fund its ambitious plans including Starlink satellite network expansion, AI infrastructure, and establishing extraterrestrial colonies.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Dow Jones flattens near 49,000 as S&P 500 hits 7,000; Fed and Big Tech earnings loom
Previous Story

Dow Jones flattens near 49,000 as S&P 500 hits 7,000; Fed and Big Tech earnings loom

Gilead stock dips as Medicare targets Biktarvy for 2028 price talks — and Trodelvy gets a guideline lift
Next Story

Gilead stock dips as Medicare targets Biktarvy for 2028 price talks — and Trodelvy gets a guideline lift

Go toTop